What a next-generation sequencing report shows

Sequencing means reading genetic code letter by letter. When it is done on cancer, the point is to find what is different about those cells.

The National Cancer Institute describes the family of tests this belongs to: biomarker testing is a way to look for genes, proteins and other substances — called biomarkers or tumour markers — that can provide information about cancer.

You will see this called many things. NCI lists tumour testing, tumour genetic testing, genomic testing, genomic profiling, molecular testing, molecular profiling, somatic testing and tumour subtyping. They overlap heavily. If your team uses a term you do not recognise, ask which of these they mean.

A sequencing report is a description of your cancer's wiring, not a verdict on your outlook.

Panels vary in scope. NCI mentions two of the broadest approaches: whole-exome sequencing examines all the genes in the cancer, while whole-genome sequencing analyses all the DNA, including genes and the regions between them.

Many reports come from narrower panels covering a defined list of genes. Broader is not automatically better — what matters is whether the test covered the changes that are relevant to your cancer type. That is a fair thing to ask.

Here is the part that trips people up. NCI explains that these tests compare your cancer cells with your healthy cells to find genetic changes, called somatic mutations, that arose during your lifetime.

The comparison is what separates "this is a change in the cancer" from "this is just how your DNA reads". Without it, ordinary human variation would look like tumour biology.

And NCI is explicit that this is a different exercise from inherited-risk testing: biomarker testing is different from genetic testing that is used to find out if someone has inherited mutations that make them more likely to get cancer. If an inherited mutation is discovered along the way, NCI says you may need another genetic test to confirm whether you truly have one.

NCI puts the output plainly: the lab will create a report that lists the biomarkers in your cancer cells and if there are any treatments that might work for you.

So a typical report has two layers. There is the raw list of what was found. And there is the interpretation — which of those findings connect to a therapy.

A finding on the list is not automatically useful. NCI states that genetic changes thought to be harmless, called benign, or whose effects are not known, called a variant of unknown significance, are not used to make treatment decisions.

That single sentence will save you hours of worry. Most lines on a sequencing report are noise. A minority are signal. Your oncologist's job is to tell you which is which.

NCI describes the payoff: the results of a biomarker test could show that your cancer has a certain biomarker that is targeted by a known therapy.

That may mean a specific drug. It may mean eligibility for a clinical trial. It may confirm that the treatment already planned is the right one. All three count as the test having done its job.

This is a common and genuinely disappointing outcome. It does not mean the test was wasted, and it does not mean nothing can be done — it means this route did not open a door.

Practical things to do at that point:

• Ask whether the panel used covered everything relevant to your cancer type.
• Ask whether there was enough tissue to complete the whole panel, since incomplete testing and negative testing are not the same thing.
• Ask about trials, which sometimes accept people on grounds other than a specific biomarker.
• Ask whether repeating the test later, on newer tissue, could ever be worthwhile.

Sequencing has genuinely changed what is possible in cancer care. It has not changed it for everyone, and being told so honestly is better than being left to wonder.